The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer - A prospective nation-wide study in Finland

Gynecologic Oncology

Volumn 115, Issue 2, 2009, Pages 199-203

  Kumpulainen, Salla ^a,b   Sankila, Risto ^b   Leminen, Arto ^c   Kuoppala, Tapio ^d   Komulainen, Marja ^e   Puistola, Ulla ^f   Hurme, Saija ^g   Hiekkanen, Heikki ^g   Mäkinen, Juha ^a   Grénman, Seija ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b FINNISH CANCER REGISTRY   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

^f OULU UNIVERSITY HOSPITAL   (Finland)

^g UNIVERSITY OF TURKU   (Finland)

Author keywords

Centralization; Operative volume; Ovarian cancer; Prognostic factors; Residual tumor; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CYCLOPHOSPHAMIDE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; FINLAND; FOLLOW UP; HUMAN; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QUESTIONNAIRE; TUMOR VOLUME; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, UNIVERSITY; HUMANS; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349972859     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.07.011     Document Type: Article

References (30)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005) 74-108
2. Barnholtz-Sloan J.S., Schwartz A.G., Qureshi R., Jacques S., Malone J., and Munkarah A.R. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am. J. Obstet. Gynecol. 189 (2003) 1120-1127
3. Huinink Ten Bokkel W.W. The treatment of ovarian cancer has reached new standards of care. Eur. J. Cancer 36 (2000) 7-9
4. Heintz A.P.M., Odicino F., Maisonneuve P., Quinn M.A., Benedet J.L., Creasman W.T., et al. Carcinoma of the ovary. Int. J. Gynaecol. Obstet. 95 (2006) S161-S192 (suppl 1)
5. Cancer in Finland 2002 and 2003. Cancer Statistics of the National Research and Development Centre for Welfare and Health. Cancer Society of Finland. Public. No 66, Helsinki 2005.
6. du Bois A., Lück H.J., Meier W., Adams H.P., Möbus V., and Costa S. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. JNCI 95 (2003) 1320-1329
7. du Bois A., Quinn M., Thigpen T., Vermorken J., Avall-Lungqvist E., Bookman M., et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference. Ann. Oncol. 16 (2005) S7-S12 (suppl 8)
8. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 (1996) 1-6
9. Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer. J. Natl. Cancer Inst. 96 (2004) 1682-1691
10. Skirnisdottir I., and Sorbe B. Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-stages III-IV) epithelial ovarian carcinoma. Int. J. Oncol. 30 (2007) 727-734
11. Bristow R.E., Zahurak M.L., del Carmen M.G., Gordon T.A., Fox H.E., Trimble E.L., and Montz F.J. Ovarian cancer surgery in Maryland: volume-based access to care. Gyn. Oncol. 93 (2004) 353-360
12. Earle C.C., Schrag D., Neville B.A., Yabroff K.R., Topor M., Fahey A., et al. Effect of surgeon speciality on processes of care and outcomes for ovarian cancer patients. J. Natl. Cancer Inst. 98 (2006) 172-180
13. Kumpulainen S., Grénman S., Kyyrönen P., Pukkala E., and Sankila R. Evidence of benefit from centralised treatment of ovarian cancer: a nationwide population-based survival analysis in Finland. Int. J. Cancer 102 (2002) 541-544
14. Paulsen T., Kjaerheim K., Kaern J., Tretli S., and Trope C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int. J. Gynecol. Cancer 16 (2006) S11-S17 (suppl 1)
15. Schrag D., Earle C., Xu F., Panageas K.S., Yabroff K.R., Bristow R.E., et al. Associations between hospital and surgeon procedure volumes and patient outcome after ovarian cancer resection. J. Natl. Cancer Inst. 98 (2006) 163-171
16. Hillner B.E., Smith T.J., and Desch C.E. Hospital and physician volume or specialization and outcome in cancer treatment: importance in quality of cancer care. J. Clin. Oncol. 18 (2000) 2327-2340
17. Oberaigner W., and Stühlinger W. Influence of department volume on cancer survival for gynaecological cancers - a population-based study in Tyrol, Austria. Gynecol. Oncol. 103 (2006) 527-534
18. Kumpulainen S., Kuoppala T., Leminen A., Penttinen J., Puistola U., Pukkala E., et al. Surgical treatment of ovarian cancer in different hospital categories - a prospective nation-wide study in Finland. Eur. J. Cancer 42 (2006) 388-395
19. Teppo L., Pukkala E., and Lehtonen M. Data quality and quality control of a population-based cancer registry. Acta. Oncol. 33 (1994) 365-369
20. Chan J.K., Urban R., Cheung M.K., Osann K., Shin J.Y., Husain A., et al. Ovarian cancer in younger vs older women: a population-based analysis. Br. J. Cancer 95 (2006) 1314-1320
21. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl. Cancer Inst. Monogr. 42 (1975) 101-104
22. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20 (2002) 1248-1259
23. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., Aghajanian C., Barakat R.R., and Chi D.S. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol. Oncol. 108 (2008) 276-281
24. Wimberg P., Lehmann N., Kimming R., Burgers A., Werner M., and Du Bois A. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An explanatory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol. Oncol. 106 (2008) 69-74
25. Vernooij F., Heintz P., Witteveen E., and van fer Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynaecologic oncologists and in specialized hospitals: a systematic review. Gynecol. Oncol. 105 (2007) 801-812
26. Andreas d.u.B.o.i.s., Rochon J., Pfisterer J., and Hoskins W.J. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol. Oncol. 112 (2008) 422-436
27. Ioka A., Tsukuma H., Ajiki W., and Oshira A. Influence of hospital procedure volume on ovarian cancer survival in Japan, a country with low incidence of ovarian cancer. Cancer Sci. 95 (2005) 233-237
28. Olaitan A., Weeks J., Mocroft A., Smith J., Howe K., and Murdoch J. The surgical management of women with ovarian cancer in the South West of England. Br. J. Cancer 85 (2001) 1824-1830
29. Oksefjell H., Sandstad B., and Trope C. Ovarian cancer stage IIIC. Consequences of treatment level on overall and progression-free survival. Eur. J. Gynaecol. Oncol. 27 (2006) 209-214
30. Vergote I., van Gorp T., Amant F., Leunen K., Neven P., and Berteloot P. Timing of debulking surgery in advanced ovarian cancer. Int. J. Gynecol. Cancer 18 Suppl 1 (2008) 11-19